INDV · Indivior Pharmaceuticals, Inc.
Market Cap
$4.12B
Shares
118.01M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-08-03 | — | |
| 8-K | 2026-08-03 | 2026-08-01 | |
| 8-K | 2026-08-03 | — | |
| 10-Q | 2026-08-03 | 2026-06-30 | |
| Investor Event Transcript | 2026-06-03 | 2026-06-30 | |
| 8-K | 2026-05-15 | 2026-05-13 | |
| 8-K | 2026-05-04 | — | |
| 8-K | 2026-04-30 | — | |
| 10-Q | 2026-04-30 | 2026-03-31 | |
| DEF 14A | 2026-03-27 | 2026-05-13 | |
| 8-K | 2026-03-17 | — | |
| 8-K | 2026-03-13 | 2026-03-12 | |
| 8-K | 2026-03-12 | — | |
| 10-K | 2026-02-26 | 2025-12-31 | |
| 8-K | 2026-02-26 | — | |
| 8-K | 2026-01-26 | 2026-01-23 | |
| 8-K | 2026-01-08 | — | |
| 8-K | 2025-12-22 | — | |
| 8-K | 2025-12-18 | 2025-12-12 | |
| 8-K | 2025-12-15 | 2025-12-11 | |
| 8-K | 2025-11-20 | — | |
| 8-K | 2025-11-14 | — | |
| 8-K/A | 2025-10-30 | 2025-08-26 | |
| 10-Q | 2025-10-30 | 2025-09-30 | |
| 8-K | 2025-10-30 | — | |
| 8-K | 2025-10-01 | — | |
| 8-K | 2025-08-26 | — | |
| 8-K | 2025-08-22 | 2025-08-20 | |
| 8-K/A | 2025-08-04 | 2025-06-20 | |
| 8-K | 2025-07-31 | — | |
| 10-Q | 2025-07-31 | 2025-06-30 | |
| 8-K | 2025-06-30 | — | |
| 8-K | 2025-06-24 | 2025-06-20 | |
| 8-K | 2025-06-02 | 2025-05-30 | |
| 8-K | 2025-06-02 | — | |
| 8-K/A | 2025-05-12 | 2025-05-08 | |
| 8-K | 2025-05-08 | — | |
| 10-Q | 2025-05-01 | 2025-03-31 | |
| 8-K | 2025-04-24 | — | |
| 8-K | 2025-03-27 | — | |
| 8-K | 2025-03-04 | 2025-03-02 | |
| 10-K | 2025-03-03 | 2024-12-31 | |
| 6-K | 2025-03-03 | — | |
| 6-K | 2025-02-28 | — | |
| 6-K | 2025-02-28 | — | |
| 6-K | 2025-02-28 | — | |
| 6-K | 2025-02-27 | — | |
| 6-K | 2025-02-27 | — | |
| 6-K | 2025-02-27 | — | |
| 6-K | 2025-02-25 | — |
Showing 1–50 of 383 filings
Key facts
CIK
1625297
CUSIP
45579U109
13F (30d)
270 filings
269 filers
Visit website
Investor relations